Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MicroRNAs and haematology: small molecules, big function.

Charles H Lawrie1

  • 1Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. charles.lawrie@ndcls.ox.ac.uk

British Journal of Haematology
|June 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Longitudinal Monitoring of Metabolic Gradients in Microreactor Culture Platforms by Raman Spectroscopy.

Biosensors·2026
Same author

MicroRNA Expression During Long-Term Treatment With 3-MCPD and Glycidol In Vitro.

Journal of applied toxicology : JAT·2025
Same author

Fibroblast Activation Protein Alpha (FAP) Expression Is Associated with Disease Recurrence and Poor Response to Tyrosine Kinase Inhibitors in Advanced Clear Cell Renal Cell Carcinoma.

International journal of molecular sciences·2025
Same author

Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research.

Materials today. Bio·2025
Same author

Solving Mazes of Organelle-Targeted Therapies with DNA Nanomachines.

Advanced materials (Deerfield Beach, Fla.)·2025
Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026
Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026
Same journal

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026
Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026
Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026
See all related articles

MicroRNAs regulate cell development and are crucial in blood cancers. Aberrant microRNA expression is linked to leukemia and lymphoma, acting as tumor suppressors or oncogenes.

Area of Science:

  • Molecular Biology
  • Genetics
  • Hematology

Background:

  • MicroRNAs (miRNAs) are small, endogenous RNAs that regulate gene expression.
  • Aberrant miRNA expression is a hallmark of various cancers, including hematological malignancies.
  • miRNAs play critical roles in normal hematopoietic development.

Purpose of the Study:

  • To review the current research on the role of microRNAs in hematopoiesis.
  • To discuss the involvement of microRNAs in the development and progression of hematological malignancies.
  • To highlight the dual role of miRNAs as tumor suppressors and oncogenes in blood cancers.

Main Methods:

  • Literature review of studies on microRNAs in hematopoiesis and hematological malignancies.
  • Analysis of research on specific microRNAs (e.g., miR-15a, miR-16-1, miR-155) in leukemia and lymphoma.

Related Experiment Videos

  • Synthesis of findings regarding miRNA regulatory functions in cellular pathways.

    • Main Results:

    • MicroRNAs are essential regulators of normal hematopoietic differentiation.
    • Specific miRNAs function as tumor suppressors (e.g., miR-15a/16-1 in leukemia) or oncogenes (e.g., miR-155, miR-17-92 cluster in lymphoma).
    • Altered miRNA expression patterns are consistently observed in hematological cancers.

    Conclusions:

    • MicroRNAs are pivotal in both normal blood cell development and the pathogenesis of hematological cancers.
    • Targeting microRNAs presents a potential therapeutic strategy for treating blood malignancies.
    • Further research is warranted to fully elucidate the complex roles of microRNAs in hematological disorders.